Role of Adjuvant Therapy in Early Non-Small Cell Lung Cancer

Martin Dietrich, MD, PhD, and Jessica Donington, MD, MSCR, provide an overview on early non-small cell lung cancer and the available treatment options.

Dr. Martin Dietrich explains the role of molecular testing in early non-small cell lung cancer.

Two experts detail the use of adjuvant therapy, including chemotherapy, in treating early non-small cell lung cancer.

Martin Dietrich, MD, PhD, describes the toxicity profiles of chemotherapy agents used in the adjuvant setting in early non-small cell lung cancer.

Dr. Jessica Donington explains how the results of the ADAURA trial changed the treatment algorithm in the adjuvant setting in early non-small cell lung cancer.

An expert oncologist details the design, outcomes, and clinical implications of the IMpower010 trial.

Jessica Donington, MD, MSCR, describes how she discusses adjuvant therapy with patients diagnosed with early non-small cell lung cancer.

Dr. Martin Dietrich reviews some factors to consider when selecting an adjuvant therapy for early non-small cell lung cancer.

An expert surgeon explains the role patients have in adjuvant therapy selection for early non-small cell lung cancer.

Dr. Jessica Donington provides an overview of key ongoing clinical trials of systemic adjuvant therapy in early non-small cell lung cancer.

Two experts explain how early-stage non-small cell lung cancer treatment has changed in recent years, particularly in the adjuvant setting, and offer future perspectives in this space.